The Food and Drug Administration approved the first treatment for the most common cause of dwarfism Friday, a drug that has proved to increase children’s height but has been polarizing among adults ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The drug has been in high demand ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The Food and Drug Administration (FDA) announced Friday that it had ...

BioMarin has won the FDA's go-ahead for its next big launch. But the drug's arrival may be unwelcome news for those who've built a community out of living full lives with dwarfism. The FDA approved ...

(Reuters) -The U.S. health regulator on Friday approved the expanded use of BioMarin Pharmaceutical's once-daily injection to treat children under the age of 5 with the most common form of ...

Add Yahoo as a preferred source to see more of our stories on Google. Feb 12 (Reuters) - BridgeBio Pharma said on Thursday its experimental therapy boosted growth rates in children ‌with a rare ...

BridgeBio licensed the exclusive Japanese rights to develop and sell an experimental dwarfism drug to Tokyo-based pharma firm Kyowa Kirin, firms said earlier this week. Terms of the deal call for ...

BridgeBio Pharma (BBIO) added ~13% in the premarket on Thursday after the company reported success in a pivotal Phase 3 trial for infigratinib, its experimental therapy for a form of dwarfism called ...

BioMarin Pharmaceutical Inc. BMRN announced that the FDA has granted approval to Voxzogo (vosoritide) injection to treat achondroplasia, a common form of dwarfism in children. Voxzogo has been ...